Updated Progression-Free Survival and Depth of Response in IKEMA, a Randomized Phase 3 Trial of Isatuximab, Carfilzomib, and Dexamethasone (Isa-Kd) Versus Kd in Relapsed Multiple Myeloma

被引：0

作者：

Martin, Thomas ^{[1
]}

Dimopoulos, Meletios-Athanasios ^{[2
]}

Mikhael, Joseph ^{[3
]}

Yong, Kwee ^{[4
]}

Capra, Marcelo ^{[5
]}

Facon, Thierry ^{[6
]}

Hajek, Roman ^{[7
,8
]}

Spicka, Ivan ^{[9
]}

Casca, France ^{[10
]}

Mace, Sandrine ^{[11
]}

Risse, Marie-Laure ^{[12
]}

Moreau, Philippe ^{[13
]}

机构：

[1] Univ Calif San Francisco, Dept Hematol, San Francisco, CA USA

[2] Natl & Kapodistrian Univ Athens, Dept Clin Therapeut, Athens, Greece

[3] Translat Genom Res Inst, City Hope Canc Ctr, Phoenix, AZ USA

[4] Univ Coll Hosp, Dept Hematol, London, England

[5] Hosp Mae Deus, Ctr Integrado Hematol Oncol, Porto Alegre, RS, Brazil

[6] Lille Univ Hosp, Dept Hematol, Lille, France

[7] Univ Ostrava, Univ Hosp Ostrava, Dept Hematooncol, Ostrava, Czech Republic

[8] Univ Ostrava, Fac Med, Ostrava, Czech Republic

[9] Charles Univ & Gen Hosp, Ist Fac Med, Dept Hematol, Dept Med, Prague, Czech Republic

[10] Ividata Life Sci Contracted Sanofi, Levallois Perret, France

[11] Sanofi R&D Translat Med, Chilly Mazarin, France

[12] Sanofi R&D, Vitry Sur Seine, France

[13] Univ Hosp Hotel Dieu, Dept Hematol, Nantes, France

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷

关键词：

MM; IKEMA; isatuximab; multiple myeloma; progression-free survival; Phase III;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MM-064

引用

页码：S403 / S404

页数：2

共 50 条

[11] Long-term outcomes with isatuximab-carfilzomib-dexamethasone (Isa-Kd) in relapsed multiple myeloma patients with 1q21+status: Updated results from the phase 3 IKEMA study.
Facon, Thierry
Moreau, Philippe
Spicka, Ivan
Suzuki, Kenshi
Yong, Kwee
Mikhael, Joseph
Fukao, Taro
Bisht, Kamlesh
Armstrong, Nicole
Mace, Sandrine
Risse, Marie-Laure
Martin, Thomas G.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[12] Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study
Thomas Martin
Meletios-Athanasios Dimopoulos
Joseph Mikhael
Kwee Yong
Marcelo Capra
Thierry Facon
Roman Hajek
Ivan Špička
Ross Baker
Kihyun Kim
Gracia Martinez
Chang-Ki Min
Ludek Pour
Xavier Leleu
Albert Oriol
Youngil Koh
Kenshi Suzuki
France Casca
Sandrine Macé
Marie-Laure Risse
Philippe Moreau
Blood Cancer Journal, 13
[13] Isatuximab Updates for Nurses: Isatuximab (Isa) Plus Carfilzomib (K) and Dexamethasone (d) Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients (IKEMA)
Wilmoth, Jenai
Marion, Sylvia
Kellam, Christine
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S420 - S421
[14] Long-Term Outcomes With Isatuximab-Carfilzomib-Dexamethasone (Isa-Kd) in Relapsed Multiple Myeloma (MM) Patients (pts) With 1q21+Status: Updated Results from the Phase 3 IKEMA Study
Facon, Thierry
Moreau, Philippe
Spicka, Ivan
Suzuki, Kenshi
Yong, Kwee
Mikhael, Joseph
Fukao, Taro
Bisht, Kamlesh
Armstrong, Nicole
Mace, Sandrine
Risse, Marie-Laure
Martin, Thomas
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S484 - S485
[15] Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed multiple myeloma (IKEMA): final overall survival analysis
Yong, Kwee
Martin, Thomas
Dimopoulos, Meletios
Mikhael, Joseph
Capra, Marcelo
Facon, Thierry
Hajek, Roman
Spicka, Ivan
Baker, Ross
Kim, Kihyun
Martinez, Gracia
Min, Chang-Ki
Pour, Ludek
Leleu, Xavier
Oriol, Albert
Koh, Youngil
Suzuki, Kenshi
Casca, France
Mace, Sandrine
Risse, Marie-Laure
Moreau, Philippe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S30 - S31
[16] Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial
Yong, Kwee
Martin, Thomas
Dimopoulos, Meletios-Athanasios
Mikhael, Joseph
Capra, Marcelo
Facon, Thierry
Hajek, Roman
Spicka, Ivan
Baker, Ross
Kim, Kihyun
Martinez, Gracia
Min, Chang-Ki
Pour, Ludek
Leleu, Xavier
Oriol, Albert
Koh, Youngil
Suzuki, Kenshi
Casca, France
Mace, Sandrine
Risse, Marie-Laure
Moreau, Philippe
LANCET HAEMATOLOGY, 2024, 11 (10): : e741 - e750
[17] Depth of Response and Response Kinetics of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Interim Analysis
Martin, Thomas
Mikhael, Joseph
Hajek, Roman
Kim, Kihyun
Suzuki, Kenshi
Hulin, Cyrille
Garg, Mamta
Quach, Hang
Sia, Hanlon
George, Anup
Konstantinova, Tatiana
Risse, Marie-Laure
Asset, Gaelle
Mace, Sandrine
van de Velde, Helgi
Moreau, Philippe
BLOOD, 2020, 136
[18] Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial
Moreau, Philippe
Dimopoulos, Meletios-Athanasios
Mikhael, Joseph
Yong, Kwee
Capra, Marcelo
Facon, Thierry
Hajek, Roman
Spicka, Ivan
Baker, Ross
Kim, Kihyun
Martinez, Gracia
Min, Chang-Ki
Pour, Ludek
Leleu, Xavier
Oriol, Albert
Koh, Youngil
Suzuki, Kenshi
Risse, Marie-Laure
Asset, Gaelle
Mace, Sandrine
Martin, Thomas
LANCET, 2021, 397 (10292): : 2361 - 2371
[19] Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design
Moreau, Philippe
Dimopoulos, Meletios A.
Yong, Kwee
Mikhael, Joseph
Risse, Marie-Laure
Asset, Gaelle
Martin, Thomas
FUTURE ONCOLOGY, 2020, 16 (02) : 4347 - 4358
[20] Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study (vol 13, 152, 2023)
Martin, Thomas
Dimopoulos, Meletios-Athanasios
Mikhael, Joseph
Yong, Kwee
Capra, Marcelo
Facon, Thierry
Hajek, Roman
Spicka, Ivan
Baker, Ross
Kim, Kihyun
Martinez, Gracia
Min, Chang-Ki
Pour, Ludek
Leleu, Xavier
Oriol, Albert
Koh, Youngil
Suzuki, Kenshi
Casca, France
Mace, Sandrine
Risse, Marie-Laure
Moreau, Philippe
BLOOD CANCER JOURNAL, 2023, 13 (01)

← 1 2 3 4 5 →